Cerecin, a global biotech company that focuses on neurometabolism, has announced a new partnership with the NIHR HealthTech Research Centre in Brain Health. This collaboration places Cerecin among other top companies like GE Healthcare, Novo Nordisk, Roche Diagnostics, and Camtech Innovations. The NIHR HealthTech Research Centre is located at King’s College London and the South London and Maudsley NHS Foundation Trust. Its main goal is to improve the diagnosis and treatment of dementia by using innovative technologies. The center uses advanced brain imaging, blood tests, computerized assessments, and digital tools to develop earlier and more effective ways to detect dementia, which will help reduce its impact on society.
Health Technology Insights: Legend Innovation Fund Commits $50Million to Mid-Atlantic BioTherapeutics
The center is led by experts such as Professor Dag Aarsland, who is the Director of the Centre for Healthy Brain Ageing at King’s College London’s Institute of Psychiatry, Psychology and Neuroscience, and Professor Clive Ballard from the University of Exeter. Together, they bring top academic research and industry experience to tackle pressing issues in brain health.
Dr. Charles Stacey, President and CEO of Cerecin, shared his excitement about the collaboration. He noted that King’s College London is globally recognized for its neuroscience research and that working with academic institutions and industry is essential to speed up progress and provide meaningful treatments for patients. He also welcomed the chance to join other industry leaders in shaping the future of brain health.
Health Technology Insights: Integrity Urgent Care Clinic Now Open in Rowlett, Texas
Dr. Richard Siow, Director of Ageing Research at King’s College London and Industry Lead for the NIHR HealthTech Research Centre in Brain Health, also welcomed Cerecin into the partnership. He emphasized that the company’s focus on neurometabolism is an important area with the potential to improve healthy brain ageing. Dr. Siow is looking forward to exploring collaboration opportunities across Cerecin’s current projects and future plans.
Cerecin is continuing to make progress with its ALTER AD study, a Phase 3 clinical trial exploring tricaprilin as a treatment for Alzheimer’s disease dementia. The company is actively looking for strategic partnerships to strengthen its position in the field, aiming to support the development of its existing treatments and new innovations, both independently and alongside other industry leaders.
Health Technology Insights: Ohio Hospital Cuts Nurse Documentation by 1500 Hours
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
